Studies on the activity of a new antimycotic (Bay b 5097) in children.
D000284:Administration, Oral; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D001555:Benzene Derivatives / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use; D002177:Candidiasis / Q000188:drug therapy*; D002179:Candidiasis, Cutaneous / Q000188:drug therapy; D002648:Child; D005767:Gastrointestinal Diseases; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D007223:Infant; D007231:Infant, Newborn; D007234:Infant, Premature; D008697:Methane; D013997:Time Factors
D000935:Antifungal Agents; D001555:Benzene Derivatives; D007093:Imidazoles; D008697:Methane